Comorbidity of allergic and autoimmune diseases in patients with autism spectrum disorder: A nationwide population-based study

2013 ◽  
Vol 7 (2) ◽  
pp. 205-212 ◽  
Author(s):  
Mu-Hong Chen ◽  
Tung-Ping Su ◽  
Ying-Sheue Chen ◽  
Ju-Wei Hsu ◽  
Kai-Lin Huang ◽  
...  
Keyword(s):  
Autism Spectrum Disorder ◽  
Autoimmune Diseases ◽  
Population Based ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Population Based Study

scholarly journals Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK

2019 ◽  
Vol 50 (2) ◽  
pp. 625-633 ◽  
Author(s):  
Basmah H. Alfageh ◽  
Kenneth K. C. Man ◽  
Frank M. C. Besag ◽  
Tariq M. Alhawassi ◽  
Ian C. K. Wong ◽  
...  
Keyword(s):  
Autism Spectrum Disorder ◽  
Psychotropic Medication ◽  
Population Based ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Population Based Study ◽  
Changing Trend ◽  
Neuropsychiatric Comorbidities ◽  
Medication Prescribing ◽  
The Uk

Abstract Autism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the prescribing of such medications is increasing.

Association between preeclampsia and autism spectrum disorder: a population‐based study

2019 ◽  
Vol 61 (2) ◽  
pp. 131-139 ◽  
Author(s):  
Gillian M. Maher ◽  
Gerard W. O'Keeffe ◽  
Christina Dalman ◽  
Patricia M. Kearney ◽  
Fergus P. McCarthy ◽  
...  
Keyword(s):  
Autism Spectrum Disorder ◽  
Population Based ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Population Based Study

scholarly journals Disparities in adversity among children with autism spectrum disorder: a population-based study

2016 ◽  
Vol 58 (11) ◽  
pp. 1124-1131 ◽  
Author(s):  
Kristin L Berg ◽  
Cheng-Shi Shiu ◽  
Kruti Acharya ◽  
Bradley C Stolbach ◽  
Michael E Msall
Keyword(s):  
Autism Spectrum Disorder ◽  
Children With Autism ◽  
Population Based ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Population Based Study

Familial coaggregation of major psychiatric disorders in first-degree relatives of individuals with autism spectrum disorder: a nationwide population-based study

2020 ◽  
pp. 1-11
Author(s):  
Hohui E. Wang ◽  
Chih-Ming Cheng ◽  
Ya-Mei Bai ◽  
Ju-Wei Hsu ◽  
Kai-Lin Huang ◽  
...  
Keyword(s):  
Autism Spectrum Disorder ◽  
Psychiatric Disorders ◽  
Population Based ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Research Database ◽  
Population Based Study ◽  
First Degree Relatives ◽  
Relative Risks ◽  
Genetic And Environmental Factors

Abstract Background Family coaggregation of attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), bipolar disorder (BD), major depressive disorder (MDD) and schizophrenia have been presented in previous studies. The shared genetic and environmental factors among psychiatric disorders remain elusive. Methods This nationwide population-based study examined familial coaggregation of major psychiatric disorders in first-degree relatives (FDRs) of individuals with ASD. Taiwan's National Health Insurance Research Database was used to identify 26 667 individuals with ASD and 67 998 FDRs of individuals with ASD. The cohort was matched in 1:4 ratio to 271 992 controls. The relative risks (RRs) and 95% confidence intervals (CI) of ADHD, ASD, BD, MDD and schizophrenia were assessed among FDRs of individuals with ASD and ASD with intellectual disability (ASD-ID). Results FDRs of individuals with ASD have higher RRs of major psychiatric disorders compared with controls: ASD 17.46 (CI 15.50–19.67), ADHD 3.94 (CI 3.72–4.17), schizophrenia 3.05 (CI 2.74–3.40), BD 2.22 (CI 1.98–2.48) and MDD 1.88 (CI 1.76–2.00). Higher RRs of schizophrenia (4.47, CI 3.95–5.06) and ASD (18.54, CI 16.18–21.23) were observed in FDRs of individuals with both ASD-ID, compared with ASD only. Conclusions The risk for major psychiatric disorders was consistently elevated across all types of FDRs of individuals with ASD. FDRs of individuals with ASD-ID are at further higher risk for ASD and schizophrenia. Our results provide leads for future investigation of shared etiologic pathways of ASD, ID and major psychiatric disorders and highlight the importance of mental health care delivered to at-risk families for early diagnoses and interventions.

Sign in / Sign up

Export Citation Format

Share Document